Luisa de Oliveira Werneck Rodrigues
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luisa de Oliveira Werneck Rodrigues has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Do Carmo Gusmão
Dermatology Departament of Federal Fluminense University, Brazil
1 shared publication - Andressa de Araújo Rodrigues
Universidade Federal de Juiz de Fora (UFJF), Internal Medicine - Juiz de Fora - Minas Gerais - Brazil
1 shared publication - Daniela de Oliveira Werneck Rodrigues
Fundação Hemominas, Juiz de Fora, MG, Brazil
1 shared publication - Jane Rocha Duarte Cintra
Instituto Oncológico Hospital Nove de Julho, Brasil
1 shared publication - Jordana Alícia Silveira Lopes
Division of Gastroenterology, Inflammatory Bowel Diseases Center, University Hospital of the Federal University of Juiz de Fora, Juiz de Fora, Brazil
1 shared publication - Nathalia Noyma Sampaio Magalhães
Faculdade de Ciências Médicas e da Saúde de Juiz de Fora. Juiz de Fora, MG. Brasil
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 18 (CP) , 1-6
Analysis of the hemotherapy support in an oncology hospital considering the COVID-19 pandemic
Objectives: The purpose of this study was to analyze the impact of COVID-19 on the use of blood components in an oncology hospital. Material and Methods: Retrospective cross-sectional quantitative nature cohort, with comparative analysis of blood component requests by an oncology hospital in the city of Juiz de Fora, Minas Gerais, Brazil, in 2019 and 2020. Results: There was a reduction of 14.36% in the requests for blood components at the oncology service in 2020 (p-value = 0,002), with a reduction of 27.33% for platelet concentrate (p-value = 0,006). The rate of attendance of Hemominas to requests for blood components at the oncology hospital was 97.99% in 2019 and 94.36% in 2020. Conclusion: The pandemic affected blood collection and supply due to the decrease in blood donors' attendance. The suspension of elective surgeries and the rational prescription of blood components allowed the rate of attendance maintenance by the blood bank. In this scenario, it is important to monitor the supply and demand for blood components in hospitals and apply strategies that optimize their use.
- 1 January 2022
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 18 (CP) , 1-6
Open AccessAnalysis of the hemotherapy support in an oncology hospital considering the COVID-19 pandemic
Objectives: The purpose of this study was to analyze the impact of COVID-19 on the use of blood components in an oncology hospital. Material and Methods: Retrospective cross-sectional quantitative nature cohort, with comparative analysis of blood component requests by an oncology hospital in the city of Juiz de Fora, Minas Gerais, Brazil, in 2019 and 2020. Results: There was a reduction of 14.36% in the requests for blood components at the oncology service in 2020 (p-value = 0,002), with a reduction of 27.33% for platelet concentrate (p-value = 0,006). The rate of attendance of Hemominas to requests for blood components at the oncology hospital was 97.99% in 2019 and 94.36% in 2020. Conclusion: The pandemic affected blood collection and supply due to the decrease in blood donors' attendance. The suspension of elective surgeries and the rational prescription of blood components allowed the rate of attendance maintenance by the blood bank. In this scenario, it is important to monitor the supply and demand for blood components in hospitals and apply strategies that optimize their use.